Looking for the Next "PSA"
Executive Summary
Cancer diagnostics has been a tough field for companies. But the need for good tests remains, and with new technologies being discovered, the opportunities still seem worth pursuing. Witness the deals signed in the field in the past half year. While none are large, they address either diagnostic companies' search for growth and high value, proprietary tests, or biotech companies' desire to foster basic research for pharmaceutical products or evaluate therapeutic impact on specific patients.